КЕРНЗ Уильям Д. (US),ФОГЕЛ Барри С. (US),ФОН Кей-Лай (US),ЧОУ Сань-Лаун (US),ВОН Дэвид (US),ЛИН Эдвард (US)
申请号：
RU2014126879
公开号：
RU2014126879A
申请日:
2012.12.02
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A dosage form containing a dose of N-acetyl homotaurinate, its calcium salt, or other pharmaceutically acceptable salt thereof, dispersed in a polymer matrix, where when administered to an object, the dosage form provides an average plasma Cacamprosate that is from about 20 to about 50% lower than plasma average sacacamprosate provided by an oral dosage form with rapid release (IR) of an equal dose. 2. A dosage form containing a dose of N-acetyl homotaurinate, a calcium salt thereof or another pharmaceutically acceptable salt thereof dispersed in a polymer matrix, where when administered to an object, the dosage form when administered to dogs provides an average T that is from about 2 to about 7 hours more than T provided by an oral dosage form with a quick release (IR) of an equal dose. 3. The dosage form according to claim 1, wherein the dose of acamprosate is from about 50 mg to less than 1 g. A dosage form according to claim 1, wherein 90% or more of the dose of acamprosate is released from the dosage form about 8 hours after administration. A dosage form according to claim 1, which includes at least one or more polymers, which is an acrylic polymer. A pharmaceutical dosage form comprising: a dose of N-acetyl homotaurinate, a calcium salt thereof or another pharmaceutically acceptable salt thereof in the range of 50 mg to 1 g； iodine or several polymers selected from a carbomer homopolymer of type B and carboxymethyl cellulose； where, when administered to an object, the dosage form provides one or more of the following: the average plasma AUC of acamprosate is equal to or significantly lower than the average AUC of aka1. Лекарственная форма, содержащая дозу N-ацетилгомотаурината, его кальциевой соли или другой его фармацевтически приемлемой соли, диспергированной в полимерной матрице, где при введении объекту, лекарственная форма обеспечивает среднее Cакампросата в плазме, что от около 20 до около 50% ниже, чем среднее Cакампросата в плазме, обеспечиваемое пе
